Morrisville’s Liquidia Settles All Litigation With United Therapeutics, Keeping YUTREPIA Available for PAH Patients
Liquidia Corporation settled all litigation with United Therapeutics, resolving six lawsuits. The agreement allows YUTREPIA, a treatment for pulmonary arterial hypertension, to remain available. Liquidia will pay $380.7 million across 2026 and 2027, funded by YUTREPIA sales and cash on hand. The company reported $222.7 million in YUTREPIA net sales for Q3 2026 and has $396.1 million in cash.
How this was made
The 30-second read
Why it matters
The settlement resolves litigation and provides certainty for PAH access, but requires label and promotional changes (PH-ILD removed, no longer promoted for PH-ILD) and imposes a sizable net payment obligation.
Market read
Traders should update valuation assumptions for Liquidia based on cleared litigation risk, the cash outlay schedule, and reduced commercialization scope from the PH-ILD label removal.
What to watch
The article notes funding plans from YUTREPIA sales and cash on hand, but does not quantify how much the $380.7M net payment changes runway or affects planned clinical study timelines beyond a general statement.
Background
Liquidia’s YUTREPIA (treprostinil inhalation powder) faced multiple lawsuits from United Therapeutics, including patent infringement claims tied to the ‘327 patent and related PH-ILD scope.
Ticker impact
Liquidia agreed to settle all six lawsuits with United Therapeutics, keep YUTREPIA available for PAH, and pay net $380.7M across 2026-2027.
Likely supportive for risk premium as litigation uncertainty clears, partially offset by the disclosed $380.7M net payment and label/promotion narrowing.
The article discloses both the legal resolution (no appeal, dismiss with prejudice, label change) and the financial obligation, which directly affects future cash flows and commercialization scope.
Market effects
Highlights ongoing patent and label-scope risk in inhaled treprostinil commercialization, potentially affecting how investors price PAH/PH-ILD differentiation claims.
Limited direct regional impact beyond North Carolina-based Liquidia operations and local litigation footprint.
Primarily US-focused (Delaware court, US label), but the settlement is described as global, which can influence international commercialization expectations.
Counterpoint
Even with litigation resolved, the label restriction (removing PH-ILD indication) and termination of Treprostinil Injection promotional support could cap growth versus prior expectations.
Key entities
- companyLiquidia Corporation
Morrisville, NC biopharmaceutical company settling six lawsuits with United Therapeutics and paying net $380.7M while keeping YUTREPIA available for PAH.
- companyUnited Therapeutics Corporation
Counterparty in the settlement, receiving net payments and having its ‘327 patent claims upheld as valid and infringed per the Delaware ruling.
- productYUTREPIA (treprostinil inhalation powder)
Liquidia’s inhaled dry-powder treprostinil therapy; settlement keeps it available for PAH and removes PH-ILD indication from the label.
